{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T14:08:19Z","timestamp":1776434899100,"version":"3.51.2"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T00:00:00Z","timestamp":1635206400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T00:00:00Z","timestamp":1635206400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s11864-021-00906-4","type":"journal-article","created":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T02:51:15Z","timestamp":1635216675000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["How to Sequence Therapies in Diffuse Large B-Cell Lymphoma Post-CAR-T Cell Failure"],"prefix":"10.1007","volume":"22","author":[{"given":"Jennifer M.","family":"Logue","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio C.","family":"Chavez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,26]]},"reference":[{"issue":"1","key":"906_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7\u201330.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"906_CR2","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","volume":"107","author":"LM Morton","year":"2006","unstructured":"Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992\u20132001. Blood. 2006;107(1):265\u201376.","journal-title":"Blood"},{"issue":"22","key":"906_CR3","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.1200\/JCO.2005.09.137","volume":"23","author":"LH Sehn","year":"2005","unstructured":"Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol. 2005;23(22):5027\u201333.","journal-title":"J Clin Oncol"},{"issue":"27","key":"906_CR4","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","volume":"28","author":"C Gisselbrecht","year":"2010","unstructured":"Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27):4184\u201390.","journal-title":"J Clin Oncol"},{"issue":"16","key":"906_CR5","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","volume":"130","author":"M Crump","year":"2017","unstructured":"Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800\u20138.","journal-title":"Blood"},{"issue":"26","key":"906_CR6","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531\u201344.","journal-title":"N Engl J Med"},{"issue":"1","key":"906_CR7","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial. Lancet Oncol. 2019;20(1):31\u201342.","journal-title":"Lancet Oncol"},{"issue":"1","key":"906_CR8","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45\u201356.","journal-title":"N Engl J Med"},{"issue":"10254","key":"906_CR9","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839\u201352.","journal-title":"Lancet"},{"issue":"Supplement 1","key":"906_CR10","first-page":"40","volume":"136","author":"C Jacobson","year":"2020","unstructured":"Jacobson C, Locke FL, Ghobadi A, et al. Long-term survival and gradual recovery of B cells in patients with refractory large B cell lymphoma treated with axicabtagene ciloleucel (axi-cel). Blood. 2020;136(Supplement 1):40\u20132.","journal-title":"Blood"},{"issue":"11","key":"906_CR11","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1016\/j.bbmt.2019.06.036","volume":"25","author":"M Byrne","year":"2019","unstructured":"\u2022\u2022 Byrne M, Oluwole OO, Savani B, Majhail NS, Hill BT, Locke FL. Understanding and managing large B cell lymphoma relapses after chimeric antigen receptor T cell therapy. Biol Blood Marrow Transplant. 2019;25(11):e344\u201351. First review article focusing on mechanisnms of relapse post CAR-T cell therapy and potential treatment options.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"27","key":"906_CR12","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","volume":"38","author":"LJ Nastoupil","year":"2020","unstructured":"Nastoupil LJ, Jain MD, Feng L, et al. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium. J Clin Oncol. 2020;38(27):3119\u201328.","journal-title":"J Clin Oncol"},{"issue":"13","key":"906_CR13","first-page":"1832","volume":"137","author":"JY Spiegel","year":"2021","unstructured":"\u2022\u2022 Spiegel JY, Dahiya S, Jain MD, et al. Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy. Blood. 2021;137(13):1832\u20135. Retrospective multicenter study that provides information of DLBCL patients relapsing after CAR-T that can be used as benchmark for future studies.","journal-title":"Blood"},{"issue":"8","key":"906_CR14","first-page":"E209","volume":"94","author":"VA Chow","year":"2019","unstructured":"\u2022\u2022 Chow VA, Gopal AK, Maloney DG, et al. Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy. Am J Hematol. 2019;94(8):E209\u201313. Retrospective single cenyter study describing the outcomes of patients relapsing after CAR-T cell therapy. It is the first study looking at this.","journal-title":"Am J Hematol"},{"issue":"23","key":"906_CR15","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1182\/blood.2019004162","volume":"135","author":"SS Neelapu","year":"2020","unstructured":"Neelapu SS, Jacobson CA, Oluwole OO, et al. Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood. 2020;135(23):2106\u20139.","journal-title":"Blood"},{"issue":"27","key":"906_CR16","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1200\/JCO.19.02103","volume":"38","author":"CA Jacobson","year":"2020","unstructured":"Jacobson CA, Hunter BD, Redd R, et al. Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity. J Clin Oncol. 2020;38(27):3095\u2013106.","journal-title":"J Clin Oncol"},{"issue":"3","key":"906_CR17","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jtct.2020.10.022","volume":"27","author":"M Garcia-Recio","year":"2021","unstructured":"Garcia-Recio M, Wudhikarn K, Pennisi M, et al. The International Prognostic Index Is associated with outcomes in diffuse large B cell lymphoma after chimeric antigen receptor t cell therapy. Transplant Cell Ther. 2021;27(3):233\u201340.","journal-title":"Transplant Cell Ther"},{"issue":"22","key":"906_CR18","doi-asserted-by":"crossref","first-page":"5607","DOI":"10.1182\/bloodadvances.2020003001","volume":"4","author":"L Vercellino","year":"2020","unstructured":"Vercellino L, Di Blasi R, Kanoun S, et al. Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma. Blood Adv. 2020;4(22):5607\u201315.","journal-title":"Blood Adv"},{"issue":"17","key":"906_CR19","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1182\/blood-2018-11-887067","volume":"133","author":"AV Hirayama","year":"2019","unstructured":"Hirayama AV, Gauthier J, Hay KA, et al. The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. Blood. 2019;133(17):1876\u201387.","journal-title":"Blood"},{"key":"906_CR20","doi-asserted-by":"crossref","unstructured":"Malek E, Sendilnathan A, Yellu M, Petersen A, Fernandez-Ulloa M, Driscoll JJ. Metabolic tumor volume on interim PET is a better predictor of outcome in diffuse large B-cell lymphoma than semiquantitative methods. Blood Cancer J. 2015;5:e326.","DOI":"10.1038\/bcj.2015.51"},{"issue":"14","key":"906_CR21","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/bloodadvances.2020001900","volume":"4","author":"EA Dean","year":"2020","unstructured":"Dean EA, Mhaskar RS, Lu H, et al. High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 2020;4(14):3268\u201376.","journal-title":"Blood Adv"},{"issue":"19","key":"906_CR22","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","volume":"4","author":"FL Locke","year":"2020","unstructured":"Locke FL, Rossi JM, Neelapu SS, et al. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 2020;4(19):4898\u2013911.","journal-title":"Blood Adv"},{"issue":"13","key":"906_CR23","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1182\/bloodadvances.2020001837","volume":"4","author":"CC Pinnix","year":"2020","unstructured":"Pinnix CC, Gunther JR, Dabaja BS, et al. Bridging therapy prior to axicabtagene ciloleucel for relapsed\/refractory large B-cell lymphoma. Blood Adv. 2020;4(13):2871\u201383.","journal-title":"Blood Adv"},{"key":"906_CR24","doi-asserted-by":"crossref","unstructured":"Jain MD, Jacobs MT, Nastoupil LJ et al. Characteristics and outcomes of patients receiving bridging therapy while awaiting manufacture of standard of care axicabtagene ciloleucel CD19 chimeric antigen receptor (CAR) T-cell therapy for relapsed\/refractory large b-cell lymphoma: results from the US Lymphoma CAR-T Consortium. Blood. 2019;134(Supplement_1):245\u2013245.","DOI":"10.1182\/blood-2019-129624"},{"issue":"12","key":"906_CR25","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/s41591-020-1061-7","volume":"26","author":"Q Deng","year":"2020","unstructured":"Deng Q, Han G, Puebla-Osorio N, et al. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nat Med. 2020;26(12):1878\u201387.","journal-title":"Nat Med"},{"issue":"8","key":"906_CR26","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1182\/blood-2018-01-828343","volume":"132","author":"J Rossi","year":"2018","unstructured":"Rossi J, Paczkowski P, Shen Y-W, et al. Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL. Blood. 2018;132(8):804\u201314.","journal-title":"Blood"},{"issue":"2","key":"906_CR27","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.19.00172","volume":"38","author":"LH Sehn","year":"2020","unstructured":"Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2020;38(2):155\u201365.","journal-title":"J Clin Oncol"},{"issue":"3","key":"906_CR28","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.clml.2020.12.013","volume":"21","author":"SD Smith","year":"2021","unstructured":"Smith SD, Lopedote P, Samara Y, et al. Polatuzumab vedotin for relapsed\/refractory aggressive B-cell lymphoma: a multicenter post-marketing analysis. Clin Lymphoma Myeloma Leuk. 2021;21(3):170\u20135.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"906_CR29","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S1470-2045(19)30091-9","volume":"20","author":"H Tilly","year":"2019","unstructured":"Tilly H, Morschhauser F, Bartlett NL, et al. Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b\u20132 study. Lancet Oncol. 2019;20(7):998\u20131010.","journal-title":"Lancet Oncol"},{"issue":"7","key":"906_CR30","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","volume":"21","author":"G Salles","year":"2020","unstructured":"Salles G, Duell J, Gonzalez Barca E, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020;21(7):978\u201388.","journal-title":"Lancet Oncol"},{"issue":"Supplement 1","key":"906_CR31","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1182\/blood-2020-140314","volume":"136","author":"KJ Maddocks","year":"2020","unstructured":"Maddocks KJ, Duell J, Gonz\u00e1lez-Barca E, et al. Long-Term subgroup analyses from L-mind, a phase ii study of tafasitamab (MOR208) combined with lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. Blood. 2020;136(Supplement 1):19\u201321.","journal-title":"Blood"},{"issue":"7","key":"906_CR32","doi-asserted-by":"crossref","first-page":"e511","DOI":"10.1016\/S2352-3026(20)30120-4","volume":"7","author":"N Kalakonda","year":"2020","unstructured":"Kalakonda N, Maerevoet M, Cavallo F, et al. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. Lancet Haematol. 2020;7(7):e511\u201322.","journal-title":"Lancet Haematol"},{"key":"906_CR33","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007512","author":"M Hamadani","year":"2020","unstructured":"Hamadani M, Radford J, Carlo-Stella C, et al. Final Results of a phase 1 study of loncastuximab tesirine in relapsed\/refractory B-cell non-Hodgkin lymphoma. Blood. 2020. https:\/\/doi.org\/10.1182\/blood.2020007512.","journal-title":"Blood"},{"issue":"Supplement 1","key":"906_CR34","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1182\/blood-2020-137524","volume":"136","author":"PF Caimi","year":"2020","unstructured":"Caimi PF, Ai WZ, Alderuccio JP, et al. Efficacy and safety of loncastuximab tesirine (ADCT-402) in relapsed\/refractory diffuse large B-cell lymphoma. Blood. 2020;136(Supplement 1):35\u20137.","journal-title":"Blood"},{"issue":"Supplement 1","key":"906_CR35","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1182\/blood-2020-142859","volume":"136","author":"FJ Hernandez-Ilizaliturri","year":"2020","unstructured":"Hernandez-Ilizaliturri FJ, Flinn IW, Kuruvilla J, et al. A phase I pharmacokinetic (PK) and safety study of Trph-222 in patients with relapsed\/refractory B-cell non-Hodgkin lymphoma (R\/R NHL): dose-escalation results. Blood. 2020;136(Supplement 1):41\u20132.","journal-title":"Blood"},{"issue":"20","key":"906_CR36","doi-asserted-by":"crossref","first-page":"5636","DOI":"10.1158\/1078-0432.CCR-13-0458","volume":"19","author":"LB John","year":"2013","unstructured":"John LB, Devaud C, Duong CP, et al. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res. 2013;19(20):5636\u201346.","journal-title":"Clin Cancer Res"},{"key":"906_CR37","doi-asserted-by":"crossref","unstructured":"Chen PH, Lipschitz M, Weirather JL et al. Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy. JCI Insight. 2020;5(12).","DOI":"10.1172\/jci.insight.134612"},{"issue":"8","key":"906_CR38","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2016-09-738245","volume":"129","author":"EA Chong","year":"2017","unstructured":"Chong EA, Melenhorst JJ, Lacey SF, et al. PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR. Blood. 2017;129(8):1039\u201341.","journal-title":"Blood"},{"issue":"6","key":"906_CR39","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1038\/s41409-019-0657-3","volume":"55","author":"BT Hill","year":"2020","unstructured":"Hill BT, Roberts ZJ, Xue A, Rossi JM, Smith MR. Rapid tumor regression from PD-1 inhibition after anti-CD19 chimeric antigen receptor T-cell therapy in refractory diffuse large B-cell lymphoma. Bone Marrow Transplant. 2020;55(6):1184\u20137.","journal-title":"Bone Marrow Transplant"},{"issue":"Supplement 1","key":"906_CR40","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1182\/blood-2018-99-119502","volume":"132","author":"EA Chong","year":"2018","unstructured":"Chong EA, Svoboda J, Dwivedy Nasta S, et al. Sequential anti-CD19 directed chimeric antigen receptor modified T-cell therapy (CART19) and PD-1 blockade with pembrolizumab in patients with relapsed or refractory B-cell non-Hodgkin lymphomas. Blood. 2018;132(Supplement 1):4198\u20134198.","journal-title":"Blood"},{"key":"906_CR41","doi-asserted-by":"crossref","unstructured":"Jaeger U, Worel N, Mcguirk JP et al. Portia: a phase 1b study evaluating safety and Efficacy of tisagenlecleucel and pembrolizumab in patients with relapsed\/refractory diffuse large B-cell lymphoma. Blood. 2019;134(Supplement_1):5325\u20135325.","DOI":"10.1182\/blood-2019-129120"},{"issue":"S2","key":"906_CR42","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/hon.128_2629","volume":"37","author":"T Siddiqi","year":"2019","unstructured":"Siddiqi T, Abramson JS, Lee HJ, et al. Safety of lisocabtagene maraleucel given with durvalumab in patients with relapsed\/refractory aggressive B-cell non Hodgkin lymphoma: first results from the platform study. Hematol Oncol. 2019;37(S2):171\u20132.","journal-title":"Hematol Oncol"},{"key":"906_CR43","doi-asserted-by":"crossref","unstructured":"Schuster SJ, Bartlett NL, Assouline S et al. Mosunetuzumab Induces Complete remissions in poor prognosis non-Hodgkin lymphoma patients, including those who are resistant to or relapsing after chimeric antigen receptor T-cell (CAR-T) therapies, and is active in treatment through multiple lines. Blood. 2019;134(Supplement_1):6\u20136.","DOI":"10.1182\/blood-2019-123742"},{"issue":"Supplement 1","key":"906_CR44","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2020-135818","volume":"136","author":"MJ Matasar","year":"2020","unstructured":"Matasar MJ, Cheah CY, Yoon DH, et al. Subcutaneous mosunetuzumab in relapsed or refractory B-cell lymphoma: promising safety and encouraging efficacy in dose escalation cohorts. Blood. 2020;136(Supplement 1):45\u20136.","journal-title":"Blood"},{"issue":"Supplement 1","key":"906_CR45","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2020-136295","volume":"136","author":"TJ Phillips","year":"2020","unstructured":"Phillips TJ, Olszewski AJ, Munoz J, et al. Mosunetuzumab, a Novel CD20\/CD3 Bispecific antibody, in combination with CHOP confers high response rates in patients with diffuse large B-cell lymphoma. Blood. 2020;136(Supplement 1):37\u20138.","journal-title":"Blood"},{"issue":"Supplement 1","key":"906_CR46","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1182\/blood-2020-136659","volume":"136","author":"R Bannerji","year":"2020","unstructured":"Bannerji R, Allan JN, Arnason JE, et al. Odronextamab (REGN1979), a human CD20 x CD3 bispecific antibody, induces durable, complete responses in patients with highly refractory B-cell non-Hodgkin lymphoma, including patients refractory to CAR T therapy. Blood. 2020;136(Supplement 1):42\u20133.","journal-title":"Blood"},{"issue":"Supplement 1","key":"906_CR47","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2020-133820","volume":"136","author":"M Hutchings","year":"2020","unstructured":"Hutchings M, Mous R, Clausen MR, et al. Subcutaneous epcoritamab induces complete responses with an encouraging safety profile across relapsed\/refractory B-cell non-Hodgkin lymphoma subtypes, including patients with prior CAR-T therapy: Updated Dose Escalation Data. Blood. 2020;136(Supplement 1):45\u20136.","journal-title":"Blood"},{"issue":"Supplement 1","key":"906_CR48","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1182\/blood-2020-136044","volume":"136","author":"M Hutchings","year":"2020","unstructured":"Hutchings M, Carlo-Stella C, Bachy E, et al. Glofitamab step-up dosing induces high response rates in patients with hard-to-treat refractory or relapsed non-Hodgkin lymphoma. Blood. 2020;136(Supplement 1):46\u20138.","journal-title":"Blood"},{"issue":"46","key":"906_CR49","doi-asserted-by":"crossref","first-page":"E10915","DOI":"10.1073\/pnas.1811615115","volume":"115","author":"M Zhang","year":"2018","unstructured":"Zhang M, Wen B, Anton OM, et al. IL-15 enhanced antibody-dependent cellular cytotoxicity mediated by NK cells and macrophages. Proc Natl Acad Sci U S A. 2018;115(46):E10915\u201324.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"906_CR50","doi-asserted-by":"crossref","unstructured":"Miyazaki T, Kivim\u00e4e S, Hennessy M et al. NKTR-255, a polymer-conjugated IL-15 enhances antibody-dependent cellular cytotoxicity mediated by NK cells in a B cell lymphoma model. Blood. 2019;134(Supplement_1):5302\u20135302.","DOI":"10.1182\/blood-2019-127771"},{"key":"906_CR51","doi-asserted-by":"crossref","unstructured":"Shah ND, Turtle CJ, Cowan AJ et al. A Phase 1, open-label, multi-center, dose escalation and dose expansion study of NKTR-255 as a single agent in relapsed or refractory hematologic malignancies and in combination with daratumumab as a salvage regimen for multiple myeloma. Blood. 2019;134(Supplement_1):4459\u20134459.","DOI":"10.1182\/blood-2019-122494"},{"issue":"8","key":"906_CR52","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","volume":"21","author":"WH Wilson","year":"2015","unstructured":"Wilson WH, Young RM, Schmitz R, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015;21(8):922\u20136.","journal-title":"Nat Med"},{"issue":"11","key":"906_CR53","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/blood.2019001160","volume":"134","author":"CS Tam","year":"2019","unstructured":"Tam CS, Trotman J, Opat S, et al. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Blood. 2019;134(11):851\u20139.","journal-title":"Blood"},{"issue":"2","key":"906_CR54","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1080\/10428194.2020.1832660","volume":"62","author":"M Coleman","year":"2021","unstructured":"Coleman M, Belada D, Casasnovas RO, et al. Phase 2 study of parsaclisib (INCB050465), a highly selective, next-generation PI3Kdelta inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202). Leuk Lymphoma. 2021;62(2):368\u201376.","journal-title":"Leuk Lymphoma"},{"issue":"13","key":"906_CR55","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1182\/blood.2018891598","volume":"134","author":"A Goy","year":"2019","unstructured":"Goy A, Ramchandren R, Ghosh N, et al. Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed\/refractory non-germinal center B-cell-like DLBCL. Blood. 2019;134(13):1024\u201336.","journal-title":"Blood"},{"issue":"Supplement 1","key":"906_CR56","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1182\/blood-2020-141447","volume":"136","author":"C Melani","year":"2020","unstructured":"Melani C, Lakhotia R, Pittaluga S, et al. Phase 1b\/2 study of vipor (venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide) in relapsed\/refractory B-cell lymphoma: safety, efficacy and molecular analysis. Blood. 2020;136(Supplement 1):44\u20135.","journal-title":"Blood"},{"issue":"1","key":"906_CR57","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm.4441","volume":"24","author":"TJ Fry","year":"2018","unstructured":"Fry TJ, Shah NN, Orentas RJ, et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med. 2018;24(1):20\u20138.","journal-title":"Nat Med"},{"issue":"10","key":"906_CR58","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1038\/s41591-020-1081-3","volume":"26","author":"NN Shah","year":"2020","unstructured":"Shah NN, Johnson BD, Schneider D, et al. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Nat Med. 2020;26(10):1569\u201375.","journal-title":"Nat Med"},{"key":"906_CR59","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009432","author":"JH Baird","year":"2020","unstructured":"Baird JH, Frank MJ, Craig J, et al. CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR-refractory large B-cell lymphoma. Blood. 2020. https:\/\/doi.org\/10.1182\/blood.2020009432.","journal-title":"Blood"},{"key":"906_CR60","doi-asserted-by":"crossref","unstructured":"Neelapu SS, Munoz J, Locke FL et al. First-in-human data of ALLO-501 and ALLO-647 in relapsed\/refractory large B-cell or follicular lymphoma (R\/R LBCL\/FL): ALPHA study. Journal of Clinical Oncology. 2020;38(15_suppl):8002\u20138002.","DOI":"10.1200\/JCO.2020.38.15_suppl.8002"},{"key":"906_CR61","doi-asserted-by":"crossref","unstructured":"Jacobson CA, Herrera AF, Budde LE et al. Initial findings of the phase 1 trial of PBCAR0191, a CD19 targeted allogeneic CAR-T cell therapy. Blood. 2019;134(Supplement_1):4107\u20134107.","DOI":"10.1182\/blood-2019-128203"},{"key":"906_CR62","doi-asserted-by":"crossref","unstructured":"Locke FL, Bartlett NL, Jacobson CA et al. Retreatment (reTx) of patients (pts) with refractory large B-cell lymphoma with axicabtagene ciloleucel (axi-cel) in ZUMA-1. Journal of Clinical Oncology. 2020;38(15_suppl):8012\u20138012.","DOI":"10.1200\/JCO.2020.38.15_suppl.8012"},{"issue":"3","key":"906_CR63","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1182\/blood.2020006770","volume":"137","author":"J Gauthier","year":"2021","unstructured":"Gauthier J, Bezerra ED, Hirayama AV, et al. Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies. Blood. 2021;137(3):323\u201335.","journal-title":"Blood"},{"issue":"15","key":"906_CR64","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1182\/bloodadvances.2020002509","volume":"4","author":"T Jain","year":"2020","unstructured":"Jain T, Knezevic A, Pennisi M, et al. Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. Blood Adv. 2020;4(15):3776\u201387.","journal-title":"Blood Adv"},{"issue":"4","key":"906_CR65","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3324\/haematol.2019.238634","volume":"106","author":"JM Logue","year":"2021","unstructured":"Logue JM, Zucchetti E, Bachmeier CA, et al. Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma. Haematologica. 2021;106(4):978\u201386.","journal-title":"Haematologica"},{"issue":"3","key":"906_CR66","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1016\/S2352-3026(20)30376-8","volume":"8","author":"C Gudiol","year":"2021","unstructured":"Gudiol C, Lewis RE, Strati P, Kontoyiannis DP. Chimeric antigen receptor T-cell therapy for the treatment of lymphoid malignancies: is there an excess risk for infection? Lancet Haematol. 2021;8(3):e216\u201328.","journal-title":"Lancet Haematol"},{"issue":"11","key":"906_CR67","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1182\/blood.2019001694","volume":"134","author":"MJ Frigault","year":"2019","unstructured":"Frigault MJ, Dietrich J, Martinez-Lage M, et al. Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma. Blood. 2019;134(11):860\u20136.","journal-title":"Blood"},{"issue":"5","key":"906_CR68","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1182\/blood-2018-09-875732","volume":"133","author":"C Grommes","year":"2019","unstructured":"Grommes C, Tang SS, Wolfe J, et al. Phase 1b trial of an ibrutinib-based combination therapy in recurrent\/refractory CNS lymphoma. Blood. 2019;133(5):436\u201345.","journal-title":"Blood"},{"issue":"13","key":"906_CR69","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1182\/bloodadvances.2017014845","volume":"2","author":"JL Rubenstein","year":"2018","unstructured":"Rubenstein JL, Geng H, Fraser EJ, et al. Phase 1 investigation of lenalidomide\/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. Blood Adv. 2018;2(13):1595\u2013607.","journal-title":"Blood Adv"},{"issue":"4","key":"906_CR70","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1016\/j.bbmt.2019.12.771","volume":"26","author":"P Dreger","year":"2020","unstructured":"Dreger P, Fenske TS, Montoto S, et al. cellular immunotherapy for refractory diffuse large B cell lymphoma in the chimeric antigen receptor-engineered T cell era: still a role for allogeneic transplantation? Biol Blood Marrow Transplant. 2020;26(4):e77\u201385.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"906_CR71","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/bjh.14046","volume":"174","author":"TS Fenske","year":"2016","unstructured":"Fenske TS, Ahn KW, Graff TM, et al. Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation. Br J Haematol. 2016;174(2):235\u201348.","journal-title":"Br J Haematol"},{"issue":"24","key":"906_CR72","doi-asserted-by":"crossref","first-page":"6157","DOI":"10.1182\/bloodadvances.2020003036","volume":"4","author":"P Dreger","year":"2020","unstructured":"Dreger P, Dietrich S, Schubert ML, et al. CAR T cells or allogeneic transplantation as standard of care for advanced large B-cell lymphoma: an intent-to-treat comparison. Blood Adv. 2020;4(24):6157\u201368.","journal-title":"Blood Adv"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-021-00906-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-021-00906-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-021-00906-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T02:23:12Z","timestamp":1638325392000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-021-00906-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,26]]},"references-count":72,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["906"],"URL":"https:\/\/doi.org\/10.1007\/s11864-021-00906-4","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,26]]},"assertion":[{"value":"24 May 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jennifer M. Logue declares that she has no conflict of interest.Julio C. Chavez has received consulting fees from Kite\/Gilead, Novartis, Karyopharm Therapeutics, Janssen, and AbbVie, and has received compensation for service on speakers\u2019 bureaus from AstraZeneca, Bristol-Myers Squibb, MorphoSys, and Epizyme.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"112"}}